Clinical Study
Hematopoietic Stem-Cell Transplantation in the Developing World: Experience from a Center in Western India
| | Conditioning regimens | Indications | Protocol |
| | Autologous HSCT | | | BEAM regimen
| Hodgkin’s lymphoma, non-Hodgkin’s lymphoma
| Day −6: Carmustine (BCNU) (300 mg/m2)
Days −5, −4, −3, −2: Etoposide (200 mg/m2)
immediately after Etoposide infusion
Cytarabine (ara-c) (400 mg/m2)
Day −1: Melphalan (140 mg/m2/dose)
Day 0: stem-cell transplant
| Melphalan regimen
| Multiple myeloma
| Day −1:
Melphalan 200 mg/m2
or
Melphalan 140 mg/m2
Day 0: stem-cell transplant
| | FluMel | NHL Follicular lymphoma | Fludarabine 30 mg/m2 for 4 days, on days −7 to −4 Melphalan 70 mg/m2 on days −3, −2
| | Allogenic HSCT | | | BuCy regimen
| AML, CML, ALL
| Days −7, −6, −5, −4: Busulfan: 3.2 mg/kg/day IV
Days −3, −2: Cyclophosphamide 60 mg/kg/day
Day 0: stem-cell transplant
| Cyclophosphamide + ATG
| Aplastic anemia
| Cyclophosphamide 200 mg/kg on days −5, −4, −3, −2; ATG 90 mg/kg on days −5, −4, −3
| | Cyclophosphamide + thiotepa + oral busulfan | Thalassemia | Days −10 to −2: oral Busulfan 4 mg/kg/day for 4 days; Thiotepa 10 mg/kg once; Cyclophosphamide 200 mg/kg over 4 days |
|
|
